Switzerland

F. Hoffmann-La Roche

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

NCRI Cancer Conference

Participation Not Confirmed

Update your events

Roche Expands Its M.S Portfolio with Investigational BTK Inhibitor Fenebrutinib and Initiates Novel Clinical Trials for Ocrevus

Lead Product(s): Fenebrutinib

Therapeutic Area: Neurology Product Name: GDC-0853

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 09, 2020

Details:

Phase III clinical trial programme initiated for investigational medicine fenebrutinib, designed to be a highly selective and reversible Bruton’s tyrosine kinase (BTK) inhibitor, in relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS).

Novartis Pharmaceuticals Corporation

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

NCRI Cancer Conference

Participation Not Confirmed

Update your events

Novartis Announces NEJM Publication of Phase III ASCLEPIOS Trials Demonstrating Superior Efficacy of Ofatumumab in Patients with Relapsing M...

Lead Product(s): Ofatumumab

Therapeutic Area: Neurology Product Name: OMB157

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 05, 2020

Details:

If approved, ofatumumab will be the first B-cell therapy that can be self-administered at home and has the potential to become a first-choice treatment for use in RMS patients.

F. Hoffmann-La Roche

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

NCRI Cancer Conference

Participation Not Confirmed

Update your events

Roche Reports Additional Safety Data of Satralizumab in NMOSD

Lead Product(s): Satralizumab

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 22, 2020

Details:

Pooled data from two pivotal Phase III open-label extension (OLE) studies show satralizumab was well-tolerated as a monotherapy or in combination with baseline immunosuppressive therapy in people with neuromyelitis optica spectrum disorder (NMOSD).